Abstract:Schistosomiasis is a major neglected parasitic disease that affects more than 240 million people worldwide caused by Platyhelminthes of the genus Schistosoma . The treatment of schistosomiasis relies on the long-term application of a single safe drug, praziquantel (PZQ). Unfortunately, PZQ is very effective on adult parasites and poorly on larval stage and immature juvenile worms; this can partially explain the re-infection in endemic areas where patients are likely to host parasites at different developmental stages concurrently. Moreover, the risk of development of drug resistance because of the widespread use of a single drug in a large population is nowadays a serious threat. Hence, research aimed at identifying novel drugs to be used alone or in combination with PZQ is needed. Schistosomes display morphologically distinct stages during their life cycle and epigenetic mechanisms are known to play important roles in parasite growth, survival, and development. Histone deacetylase (HDAC) enzymes, particularly HDAC8, are considered valuable for therapeutic intervention for the treatment of schistosomiasis. Herein, we report the phenotypic screening on both larvae and adult Schistosoma mansoni stages of structurally different HDAC inhibitors selected from the in-house Siena library. All molecules have previously shown inhibition profiles on human HDAC6 and/or HDAC8 enzymes. Among them we identified a quinolone-based HDAC inhibitor, NF2839, that impacts larval and adult parasites as well as egg viability and maturation in vitro . Importantly, this quinolone-based compound also increases histone and tubulin acetylation in S . mansoni parasites, thus representing a leading candidate for the development of new generation anti-Schistosoma chemotherapeutics. Neglected tropical diseases, such as schistosomiasis, which is caused by parasitic worms, represent serious public health problems in many countries around the world. Schistosoma mansoni is the major parasitic platyhelminth species causing intestinal schistosomiasis. Currently the control of schistosomiasis is heavily reliant on the drug praziquantel (PZQ) that it is unfortunately not highly effective against larval and immature worm stages. The use of PZQ in mass treatment programs means that the development of resistance is likely, therefore identifying novel drug targets and their associated compounds is critical. Drugs that inhibit enzymes that modify the chromatin structure have been developed for several diseases. We and others have shown that S . mansoni epigenetic enzymes are also potential therapeutic targets. Here, we evaluate and characterize several histone deacetylases (HDAC) inhibitors on the larval and adult stage of Schistosoma mansoni and report the anti-parasitic profile of these compounds. Some of the HDAC inhibitors tested showed potent effects, particularly NF2839, that impacts larval and adult parasites as well as egg viability and maturation. The findings of this study provide a starting point for the development of new HDAC-based schistosomicidal compounds.

Schiff bases complexed with iron and their relation with the life cycle and infection by Schistosoma mansoni

Treatment of acute schistosomiasis mansoni with praziquantel and an antifibrotic agent in mice. Maintenance of resistance to infection

Evaluation of the prophylactic and therapeutic efficacies of mucus and tissue nucleoproteins extracted from Biomphalaria alexandrina snails on schistosomiasis mansoni

Anti-Inflammatory Properties of Menthol and Menthone in Schistosoma mansoni Infection

Effects of Abelmoschus esculentus Extracts and Fractions on Embryos and Adult Individuals of Biomphalaria glabrata (Say, 1818) and on Schistosoma mansoni Cercariae

Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni

Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds

Schistosomicidal, hepatoprotective and antioxidant activities of the N-acetyl-L-cysteine and/or praziquantel in experimental acute mansonic schistosomiasis

Integration and use of Schistosoma mansoni genomic data towards the identification of candidate therapeutic targets

Dietary glycemic and energy load differentially modulates Schistosoma mansoni-induced granulomatous inflammation and response to antiparasitic chemotherapy

HGPRT and PNP: Recombinant Enzymes from Schistosoma mansoni and Their Role in Immunotherapy during Experimental Murine Schistosomiasis

Schistosoma mansoni FES Tyrosine Kinase Involvement in the Mammalian Schistosomiasis Outcome and Miracidia Infection Capability in Biomphalaria glabrata

In vitro and in vivo efficacy of the amiodarone and praziquantel combination against the blood fluke Schistosoma mansoni

Immune response of mice infected with Schistosoma mansoni is modulated by antifibrotic treatment

Sanguinarine: an alkaloid with promising in vitro and in vivo antiparasitic activity against different developmental stages of Schistosoma mansoni and in silico pharmacokinetic properties (ADMET)

The synergistic effect of Ficus carica nanoparticles and Praziquantel on mice infected by Schistosoma mansoni cercariae

High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni

Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection

High pesticide tolerance of S. mansoni: implications for the risk of schistosomiasis

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S . mansoni larval and adult worm stages

Mass spectrometry imaging: a new vision in differentiating Schistosoma mansoni strains